Jason McCarthy

Maxim Group | Healthcare

Jason McCarthy is an analyst from Maxim Group specializing in the Healthcare sector. Ranked #1575 out of 4773 analysts, they have issued 29 stock ratings with a success rate of 65.57% and an average return of 42.46%.

Jason McCarthy has a well-established track record, with 29 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 65.57% and an average return of 42.46%, underscoring their expertise and ability to identify winning opportunities for investors.

#1575

Out of 4773

29

Total Ratings

+65.57%

Success Rate

+42.46%

Average Return

Recent Ratings Analysis

AKTX

Jul 20, 2026

Target

$30.00

Current

$11.30

Performance

6.00%

Jason McCarthy rated AKTX as Buy on Jul 20, 2026, setting a price target of 30. The call has proven timely, with shares rising 6.00% toward the price target of 30.

RNTX

Jul 20, 2026

Target

$4.00

Current

$0.79

Performance

-6.99%

On Jul 20, 2026, RNTX was given a Buy rating by Jason McCarthy, with a target price of 4. Despite the Buy call, shares fell from 0.785 to 0.785, challenging the optimistic stance.

CNTX

Jun 16, 2026

Target

$4.00

Current

$0.35

Performance

-46.12%

CNTX received a Buy rating from Jason McCarthy on Jun 16, 2026, aiming for 4. The rating hasn’t played out as hoped, with the stock trading 46.12% below expectations.

ZVRA

Jun 10, 2026

Target

$35.00

Current

$12.01

Performance

-11.04%

On Jun 10, 2026, Jason McCarthy published a Buy outlook on ZVRA, with a target of 35. Market action contradicted the Buy thesis, as shares slipped to 12.01.

RZLT

Jun 03, 2026

Target

$14.00

Current

$4.22

Performance

-7.86%

Jason McCarthy on Jun 03, 2026 assigned RZLT a Buy rating, with a price target of 14. The call has struggled to gain traction, with shares losing 7.86%.

FLNA

May 26, 2026

Target

$5.00

Current

$0.77

Performance

-45.21%

On May 26, 2026, Jason McCarthy reaffirmed FLNA with a Buy rating, targeting 5. Shares slid 45.21% despite the recommendation, highlighting downside risks.

NTHI

May 18, 2026

Target

$20.00

Current

$3.68

Performance

-31.09%

NTHI was rated Buy by Jason McCarthy on May 18, 2026, with a price objective of 20. This case shows how bullish projections can fail, with the stock now below 3.68.

CMPS

May 15, 2026

Target

$20.00

Current

$14.35

Performance

38.38%

On May 15, 2026, Jason McCarthy initiated coverage on CMPS with a Buy rating and target of 20. The stock’s climb of 38.38% since the call highlights the foresight in the rating.

IMNN

Apr 17, 2026

Target

$10.00

Current

$1.47

Performance

-52.58%

Jason McCarthy issued a Buy recommendation for IMNN on Apr 17, 2026, price target set at 10. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

TOVX

Mar 31, 2026

Target

$1.00

Current

$0.25

Performance

26.46%

On Mar 31, 2026, TOVX was evaluated by Jason McCarthy, who gave a Buy rating and target of 1. This case illustrates how a timely bullish rating can translate into tangible gains of 26.46%.

MNOV

Mar 23, 2026

Target

$6.00

Current

$1.81

Performance

24.83%

Jason McCarthy rated MNOV as Buy on Mar 23, 2026, setting a price target of 6. The call has proven timely, with shares rising 24.83% toward the price target of 6.

SLS

Mar 12, 2026

Target

$10.00

Current

$11.54

Performance

129.52%

On Mar 12, 2026, SLS was given a Buy rating by Jason McCarthy, with a target price of 10. The stock rallied 129.52% after the rating, narrowing the gap to the target of 10 and validating the bullish stance.

CLRB

Mar 10, 2026

Target

$10.00

Current

$2.31

Performance

-24.26%

CLRB received a Buy rating from Jason McCarthy on Mar 10, 2026, aiming for 10. The rating hasn’t played out as hoped, with the stock trading 24.26% below expectations.

PLYX

Feb 27, 2026

Target

$10.00

Current

$2.01

Performance

-34.10%

On Feb 27, 2026, Jason McCarthy published a Buy outlook on PLYX, with a target of 10. Market action contradicted the Buy thesis, as shares slipped to 2.01.

CODX

Jan 23, 2026

Target

—

Current

$1.12

Performance

-62.54%

Jason McCarthy on Jan 23, 2026 assigned CODX a Hold rating, with a price target of null. The call successfully avoided chasing as shares lost 62.54%.

VTGN

Dec 17, 2025

Target

—

Current

$0.24

Performance

-72.47%

On Dec 17, 2025, Jason McCarthy reaffirmed VTGN with a Hold rating, targeting null. The Hold stance reflected market caution that was later justified.

CAPR

Dec 04, 2025

Target

$50.00

Current

$8.37

Performance

-67.05%

CAPR was rated Buy by Jason McCarthy on Dec 04, 2025, with a price objective of 50. This case shows how bullish projections can fail, with the stock now below 8.37.

ARTL

Nov 19, 2025

Target

—

Current

$5.43

Performance

-89.13%

On Nov 19, 2025, Jason McCarthy initiated coverage on ARTL with a Hold rating and target of null. The rating matched the stock’s inability to hold above 5.43.

CERO

Nov 03, 2025

Target

—

Current

$0.01

Performance

—

Jason McCarthy issued a Hold recommendation for CERO on Nov 03, 2025, price target set at null. The rating was appropriate for a consolidating market trading near 0.01037.

ABP

Oct 21, 2025

Target

—

Current

$0.52

Performance

-91.33%

On Oct 21, 2025, ABP was evaluated by Jason McCarthy, who gave a Hold rating and target of null. The Hold call avoided chasing into subsequent weakness of 91.33%.

GANX

Oct 07, 2025

Target

$7.00

Current

$1.75

Performance

-13.37%

Jason McCarthy rated GANX as Buy on Oct 07, 2025, setting a price target of 7. The stock has underperformed, dropping 13.37% despite the bullish target of 7.

HIND

Oct 02, 2025

Target

$15.00

Current

$2.06

Performance

-61.57%

On Oct 02, 2025, HIND was given a Buy rating by Jason McCarthy, with a target price of 15. Despite the Buy call, shares fell from 2.06 to 2.06, challenging the optimistic stance.

ADIL

Sep 30, 2025

Target

$1.50

Current

$4.90

Performance

-44.56%

ADIL received a Buy rating from Jason McCarthy on Sep 30, 2025, aiming for 1.5. The rating hasn’t played out as hoped, with the stock trading 44.56% below expectations.

AZTR

Sep 24, 2025

Target

$4.00

Current

$0.18

Performance

-76.22%

On Sep 24, 2025, Jason McCarthy published a Buy outlook on AZTR, with a target of 4. Market action contradicted the Buy thesis, as shares slipped to 0.1781.

CNSP

Sep 12, 2025

Target

$20.00

Current

$5.84

Performance

-20.97%

Jason McCarthy on Sep 12, 2025 assigned CNSP a Buy rating, with a price target of 20. The call has struggled to gain traction, with shares losing 20.97%.

NEUP

Sep 11, 2025

Target

$35.00

Current

$3.73

Performance

-73.34%

On Sep 11, 2025, Jason McCarthy reaffirmed NEUP with a Buy rating, targeting 35. Shares slid 73.34% despite the recommendation, highlighting downside risks.

CHRS

Sep 04, 2025

Target

$4.00

Current

$1.33

Performance

1.53%

CHRS was rated Buy by Jason McCarthy on Sep 04, 2025, with a price objective of 4. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

PSTV

Aug 18, 2025

Target

$3.00

Current

$3.87

Performance

-71.13%

On Aug 18, 2025, Jason McCarthy initiated coverage on PSTV with a Buy rating and target of 3. The Buy call has yet to be validated as shares remain -0.87 away from the target.

RVPH

Aug 15, 2025

Target

$2.00

Current

$0.53

Performance

-95.05%

Jason McCarthy issued a Buy recommendation for RVPH on Aug 15, 2025, price target set at 2. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

BCLI

Jul 23, 2025

Target

—

Current

$1.07

Performance

49.70%

On Jul 23, 2025, BCLI was evaluated by Jason McCarthy, who gave a Hold rating and target of null. Investors who stayed in despite the Hold saw upside of 49.70%.

INMB

Jul 02, 2025

Target

$8.00

Current

$2.22

Performance

-5.93%

Jason McCarthy rated INMB as Buy on Jul 02, 2025, setting a price target of 8. The stock has underperformed, dropping 5.93% despite the bullish target of 8.

KZIA

Jun 11, 2025

Target

$15.00

Current

$11.19

Performance

17.30%

On Jun 11, 2025, KZIA was given a Buy rating by Jason McCarthy, with a target price of 15. The stock rallied 17.30% after the rating, narrowing the gap to the target of 15 and validating the bullish stance.

KAPA

Mar 27, 2025

Target

$4.00

Current

$1.75

Performance

-74.23%

KAPA received a Buy rating from Jason McCarthy on Mar 27, 2025, aiming for 4. The rating hasn’t played out as hoped, with the stock trading 74.23% below expectations.

MBRX

Mar 25, 2025

Target

$4.00

Current

$0.71

Performance

-97.51%

On Mar 25, 2025, Jason McCarthy published a Buy outlook on MBRX, with a target of 4. Market action contradicted the Buy thesis, as shares slipped to 0.715.

ANIX

Mar 21, 2025

Target

$10.00

Current

$2.76

Performance

-12.66%

Jason McCarthy on Mar 21, 2025 assigned ANIX a Buy rating, with a price target of 10. The call has struggled to gain traction, with shares losing 12.66%.

ONCY

Mar 10, 2025

Target

$3.00

Current

$0.75

Performance

16.12%

On Mar 10, 2025, Jason McCarthy reaffirmed ONCY with a Buy rating, targeting 3. The recommendation was supported by strong follow-through as the stock rose from 0.7455 to 0.7455.

ATHE

Jan 30, 2025

Target

$12.00

Current

$4.05

Performance

-11.38%

ATHE was rated Buy by Jason McCarthy on Jan 30, 2025, with a price objective of 12. This case shows how bullish projections can fail, with the stock now below 4.05.

NAYA

Jan 23, 2025

Target

$2.00

Current

$2.20

Performance

-60.82%

On Jan 23, 2025, Jason McCarthy initiated coverage on NAYA with a Buy rating and target of 2. The Buy call has yet to be validated as shares remain -0.20 away from the target.

MDCX

Dec 17, 2024

Target

$10.00

Current

$0.16

Performance

-93.84%

Jason McCarthy issued a Buy recommendation for MDCX on Dec 17, 2024, price target set at 10. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

BLTE

Nov 15, 2024

Target

$110.00

Current

$173.79

Performance

109.87%

On Nov 15, 2024, BLTE was evaluated by Jason McCarthy, who gave a Buy rating and target of 110. This case illustrates how a timely bullish rating can translate into tangible gains of 109.87%.

AIM

Oct 22, 2024

Target

$1.00

Current

$0.22

Performance

-17.58%

Jason McCarthy rated AIM as Buy on Oct 22, 2024, setting a price target of 1. The stock has underperformed, dropping 17.58% despite the bullish target of 1.

MESO

Sep 24, 2024

Target

$12.00

Current

$15.48

Performance

112.93%

On Sep 24, 2024, MESO was given a Buy rating by Jason McCarthy, with a target price of 12. The stock rallied 112.93% after the rating, narrowing the gap to the target of 12 and validating the bullish stance.

CYTH

Aug 27, 2024

Target

—

Current

$0.72

Performance

-9.36%

CYTH received a Hold rating from Jason McCarthy on Aug 27, 2024, aiming for null. The Hold stance proved prudent, with the market softening by 9.36%.

SNPX

Jul 11, 2024

Target

$14.00

Current

$7.85

Performance

80.05%

On Jul 11, 2024, Jason McCarthy published a Buy outlook on SNPX, with a target of 14. Shares gained 80.05%, underscoring the accuracy of the bullish outlook toward 14.

VIRI

Jun 20, 2024

Target

$1.00

Current

$0.15

Performance

-97.62%

Jason McCarthy on Jun 20, 2024 assigned VIRI a Buy rating, with a price target of 1. The call has struggled to gain traction, with shares losing 97.62%.

NRBO

May 08, 2024

Target

$10.00

Current

$2.36

Performance

-39.95%

On May 08, 2024, Jason McCarthy reaffirmed NRBO with a Buy rating, targeting 10. Shares slid 39.95% despite the recommendation, highlighting downside risks.

Frequency Asked Questions

Who is Jason McCarthy?

Jason McCarthy is an analyst from Maxim Group specializing in the Healthcare sector.

What is Jason McCarthy's success rate?

Jason McCarthy currently has a success rate of +65.57%.

How many ratings has Jason McCarthy issued?

Jason McCarthy has issued 29 stock ratings so far.

What is the average return of Jason McCarthy's calls?

Their stock ratings have generated an average return of +42.46%.

What is Jason McCarthy's ranking?

Jason McCarthy is ranked #1575 out of 4773 analysts.

What types of ratings does Jason McCarthy give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Jason McCarthy?

You can follow Jason McCarthy by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Jason McCarthy?

Their latest rating was a Buy on AKTX issued on 2026-07-20.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep